Gene expression profiling of ATL patients

Compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability

Cynthia A. Pise-Masison, Michael Radonovich, Kathleen Dohoney, John C. Morris, Deirdre O'Mahony, Min Jung Lee, Jane Trepel, Thomas A. Waldmann, John Edward Janik, John N. Brady

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Adult T-cell leukemia/lymphoma (ATL) is an aggressive and fatal disease. We have examined 32 patients with smoldering, chronic, lymphoma and acute leukemia using Affymetrix HG-U133A2.0 arrays. Using the BRB array program, we identified genes differentially expressed in leukemia cells compared with normal lymphocytes. Several unique genes were identified that were overexpressed in leukemic cells, including TNFSF11, RGS13, MAFb, CSPG2, C/EBP-α, and TCF4; 200 of the most highly overexpressed ATL genes were analyzed by the Pathway Studio, version 4.0 program. ATL leukemia cells were characterized by an increase in genes linked to "central" genes CDC2/cyclin B1, SYK/LYN, proliferating cell nuclear antigen, and BIRC5. Because of its potential therapeutic importance, we focused our studies on the regulation and function of BIRC5, whose expression was increased in 13 of 14 leukemia samples. TCF4 reporter assays and transfection of DN-TCF4 demonstrated that TCF4 regulates BIRC5 gene expression. Functionally, transfection of ATL cells with BIRC5 shRNA decreased BIRC5 expression and cell viability 80%. Clinical treatment of ATL patients with Zenapax or bortezomib decreased BIRC5 expression and cell viability. These experiments represent the first direct experimental evidence that BIRC5 plays an important role in ATL cell viability and provides important insight into ATL genesis and potential targeted therapies.

Original languageEnglish (US)
Pages (from-to)4016-4026
Number of pages11
JournalBlood
Volume113
Issue number17
DOIs
StatePublished - Nov 17 2009

Fingerprint

Adult T Cell Leukemia Lymphoma
T-cells
Gene Expression Profiling
Gene expression
Cell Survival
Genes
Cells
Gene Expression
Leukemia
Transfection
Cyclin B1
Lymphocytes
Studios
Proliferating Cell Nuclear Antigen
Small Interfering RNA
Assays
Lymphoma
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Pise-Masison, C. A., Radonovich, M., Dohoney, K., Morris, J. C., O'Mahony, D., Lee, M. J., ... Brady, J. N. (2009). Gene expression profiling of ATL patients: Compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood, 113(17), 4016-4026. https://doi.org/10.1182/blood-2008-08-175901

Gene expression profiling of ATL patients : Compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. / Pise-Masison, Cynthia A.; Radonovich, Michael; Dohoney, Kathleen; Morris, John C.; O'Mahony, Deirdre; Lee, Min Jung; Trepel, Jane; Waldmann, Thomas A.; Janik, John Edward; Brady, John N.

In: Blood, Vol. 113, No. 17, 17.11.2009, p. 4016-4026.

Research output: Contribution to journalArticle

Pise-Masison, CA, Radonovich, M, Dohoney, K, Morris, JC, O'Mahony, D, Lee, MJ, Trepel, J, Waldmann, TA, Janik, JE & Brady, JN 2009, 'Gene expression profiling of ATL patients: Compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability', Blood, vol. 113, no. 17, pp. 4016-4026. https://doi.org/10.1182/blood-2008-08-175901
Pise-Masison, Cynthia A. ; Radonovich, Michael ; Dohoney, Kathleen ; Morris, John C. ; O'Mahony, Deirdre ; Lee, Min Jung ; Trepel, Jane ; Waldmann, Thomas A. ; Janik, John Edward ; Brady, John N. / Gene expression profiling of ATL patients : Compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. In: Blood. 2009 ; Vol. 113, No. 17. pp. 4016-4026.
@article{c85b90ce015c4b3e87dde12e84279273,
title = "Gene expression profiling of ATL patients: Compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability",
abstract = "Adult T-cell leukemia/lymphoma (ATL) is an aggressive and fatal disease. We have examined 32 patients with smoldering, chronic, lymphoma and acute leukemia using Affymetrix HG-U133A2.0 arrays. Using the BRB array program, we identified genes differentially expressed in leukemia cells compared with normal lymphocytes. Several unique genes were identified that were overexpressed in leukemic cells, including TNFSF11, RGS13, MAFb, CSPG2, C/EBP-α, and TCF4; 200 of the most highly overexpressed ATL genes were analyzed by the Pathway Studio, version 4.0 program. ATL leukemia cells were characterized by an increase in genes linked to {"}central{"} genes CDC2/cyclin B1, SYK/LYN, proliferating cell nuclear antigen, and BIRC5. Because of its potential therapeutic importance, we focused our studies on the regulation and function of BIRC5, whose expression was increased in 13 of 14 leukemia samples. TCF4 reporter assays and transfection of DN-TCF4 demonstrated that TCF4 regulates BIRC5 gene expression. Functionally, transfection of ATL cells with BIRC5 shRNA decreased BIRC5 expression and cell viability 80{\%}. Clinical treatment of ATL patients with Zenapax or bortezomib decreased BIRC5 expression and cell viability. These experiments represent the first direct experimental evidence that BIRC5 plays an important role in ATL cell viability and provides important insight into ATL genesis and potential targeted therapies.",
author = "Pise-Masison, {Cynthia A.} and Michael Radonovich and Kathleen Dohoney and Morris, {John C.} and Deirdre O'Mahony and Lee, {Min Jung} and Jane Trepel and Waldmann, {Thomas A.} and Janik, {John Edward} and Brady, {John N.}",
year = "2009",
month = "11",
day = "17",
doi = "10.1182/blood-2008-08-175901",
language = "English (US)",
volume = "113",
pages = "4016--4026",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "17",

}

TY - JOUR

T1 - Gene expression profiling of ATL patients

T2 - Compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability

AU - Pise-Masison, Cynthia A.

AU - Radonovich, Michael

AU - Dohoney, Kathleen

AU - Morris, John C.

AU - O'Mahony, Deirdre

AU - Lee, Min Jung

AU - Trepel, Jane

AU - Waldmann, Thomas A.

AU - Janik, John Edward

AU - Brady, John N.

PY - 2009/11/17

Y1 - 2009/11/17

N2 - Adult T-cell leukemia/lymphoma (ATL) is an aggressive and fatal disease. We have examined 32 patients with smoldering, chronic, lymphoma and acute leukemia using Affymetrix HG-U133A2.0 arrays. Using the BRB array program, we identified genes differentially expressed in leukemia cells compared with normal lymphocytes. Several unique genes were identified that were overexpressed in leukemic cells, including TNFSF11, RGS13, MAFb, CSPG2, C/EBP-α, and TCF4; 200 of the most highly overexpressed ATL genes were analyzed by the Pathway Studio, version 4.0 program. ATL leukemia cells were characterized by an increase in genes linked to "central" genes CDC2/cyclin B1, SYK/LYN, proliferating cell nuclear antigen, and BIRC5. Because of its potential therapeutic importance, we focused our studies on the regulation and function of BIRC5, whose expression was increased in 13 of 14 leukemia samples. TCF4 reporter assays and transfection of DN-TCF4 demonstrated that TCF4 regulates BIRC5 gene expression. Functionally, transfection of ATL cells with BIRC5 shRNA decreased BIRC5 expression and cell viability 80%. Clinical treatment of ATL patients with Zenapax or bortezomib decreased BIRC5 expression and cell viability. These experiments represent the first direct experimental evidence that BIRC5 plays an important role in ATL cell viability and provides important insight into ATL genesis and potential targeted therapies.

AB - Adult T-cell leukemia/lymphoma (ATL) is an aggressive and fatal disease. We have examined 32 patients with smoldering, chronic, lymphoma and acute leukemia using Affymetrix HG-U133A2.0 arrays. Using the BRB array program, we identified genes differentially expressed in leukemia cells compared with normal lymphocytes. Several unique genes were identified that were overexpressed in leukemic cells, including TNFSF11, RGS13, MAFb, CSPG2, C/EBP-α, and TCF4; 200 of the most highly overexpressed ATL genes were analyzed by the Pathway Studio, version 4.0 program. ATL leukemia cells were characterized by an increase in genes linked to "central" genes CDC2/cyclin B1, SYK/LYN, proliferating cell nuclear antigen, and BIRC5. Because of its potential therapeutic importance, we focused our studies on the regulation and function of BIRC5, whose expression was increased in 13 of 14 leukemia samples. TCF4 reporter assays and transfection of DN-TCF4 demonstrated that TCF4 regulates BIRC5 gene expression. Functionally, transfection of ATL cells with BIRC5 shRNA decreased BIRC5 expression and cell viability 80%. Clinical treatment of ATL patients with Zenapax or bortezomib decreased BIRC5 expression and cell viability. These experiments represent the first direct experimental evidence that BIRC5 plays an important role in ATL cell viability and provides important insight into ATL genesis and potential targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=65449155163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449155163&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-08-175901

DO - 10.1182/blood-2008-08-175901

M3 - Article

VL - 113

SP - 4016

EP - 4026

JO - Blood

JF - Blood

SN - 0006-4971

IS - 17

ER -